AIVITA Biomedical CEO Hans Keirstead, Ph.D. to Present as Distinguished Speaker at Upcoming Stem Cell Summit 2017

Dr. Keirstead will speak about AIVITA’s Phase 2 cancer therapy development and cosmetic product commercialization

IRVINE, Calif. – April 3, 2017 – AIVITA Biomedical today announced that Chief Executive Officer Hans Keirstead, Ph.D. will be speaking at the upcoming Stem Cell Summit in Boston, Massachusetts. The conference, taking place April 5-7 at the Hyatt Regency, will be attended by academics and industry representatives seeking the latest developments in all aspects of stem cell research, development and commercialization.

Stem Cell Summit 2017 is a three-day conference which provides information on cutting-edge developments in all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development and the commercialization of stem cells.

AIVITA’s CEO, Hans Keirstead, Ph.D., will speak on Friday, April 7th to present a talk titled “Stem Cell Product Development and Commercialization,” drawing on his extensive experience in advancing stem cell-based technologies from research discovery to commercial viability. AIVITA’s business plan typifies the session titled “Commercialization: Creating Sustainable Business Models.”

“I’m excited to see old friends and new programs, while taking part in this cornerstone meeting for the field,” said Dr. Keirstead.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. For more information, visit